A new 15-year chart review has revealed concerning evidence about Post-SSRI S*xual Dysfunction (PSSD), a condition affecting patients who develop persistent intimate health problems after using common antidepressants.
The comprehensive study, published in The Journal of S*xual Medicine, examined 43 men with an average age of 27.6 years who experienced ongoing dysfunction for at least six months after stopping selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs). This represents the largest clinical review of PSSD to date.
The findings paint a troubling picture of young, otherwise healthy men facing severe complications. An overwhelming 88% reported ED, while 92% experienced reduced sensation. Patients also described diminished desire and problems with completion, causing significant personal distress with an average S*xual Distress Scale score of 37.4.
The biologic pathophysiology of ED is hypothesized to result from an effect of the oral SSRI/SNRI leading to increased oxygen radical formation causing cavernosal smooth muscle apoptosis in affected patients
the researchers stated.
What makes these findings particularly concerning is the severity of symptoms in such a young population. The mean E function score was 8.8, consistent with severe dysfunction, in men averaging their late twenties without typical risk factors like cardiovascular disease or diabetes.
Advanced imaging revealed tissue changes typically seen in much older men with vascular problems. Ultrasound examinations showed abnormal tissue patterns throughout the shaft similar to men in their mid-60s with blood flow issues, rather than the normal patterns expected in younger patients.
Researchers also conducted quantitative sensory testing, discovering that 89% of patients showed abnormal results in vibration, heat, and cold perception thresholds. Hormone testing ruled out endocrine causes, with testosterone and other hormone levels falling within normal ranges.
The research team hypothesizes that these SSRIs may trigger lasting changes through two distinct mechanisms. Physical symptoms may result from cellular damage within the responsible tissue caused by oxidative stress. Meanwhile, changes in desire, sensation, and completion likely stem from altered brain neurotransmitter activity.
Dr. A. Goldstein and colleagues emphasize that while intimate side effects from SSRIs typically resolve after stopping, PSSD represents a distinct phenomenon where symptoms persist indefinitely in susceptible individuals.
This research raises important questions about informed consent and medication counseling for patients prescribed these commonly used antidepressants, particularly younger individuals without previous intimate health concerns.
